Genmab A/S Sponsored ADR (GMAB) vs Jazz Pharmaceuticals PLC (JAZZ)
Genmab A/S Sponsored ADR and Jazz Pharmaceuticals PLC are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $20.8B against $15.3B — 1.4× the size. Jazz Pharmaceuticals PLC trades at the lower P/E: 15.6× against 27.8×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 12.6%. Jazz Pharmaceuticals PLC has the higher net margin (20.5% vs 19.1%) and the higher return on invested capital (8.06% vs 6.99%). Across the 21 metrics below, Jazz Pharmaceuticals PLC leads on 12 and Genmab A/S Sponsored ADR on 9.
Valuation
Profitability
| Metric | GMAB | JAZZ | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.03% | 88.42% | 65.16% |
| Operating margin | 25.95% | 19.49% | 0.00% |
| Net margin | 19.08% | 20.45% | 0.00% |
| Free cash flow margin | (153.64%) | 30.79% | 0.00% |
| Return on equity | 14.00% | 22.11% | (57.72%) |
| Return on assets | 8.30% | 8.54% | (49.22%) |
| Return on invested capital | 6.99% | 8.06% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack